Role of VEGF and CD44v6 in differentiating benign from malignant ascites.
OBJECTIVE
To detect the vascular endothelial growth factor (VEGF) and soluble splice variant 6 of CD44 (sCD44v6) levels in ascites and to explore their role in differentiating benign from malignant ascites.


METHODS
Cirrhotic ascites (n=36), tuberculosis ascites (n=8) and malignant ascites (n=23) were collected and studied. Concentrations of soluble VEGF and sCD44v6 in various kinds of ascites (n=67) were measured using a sandwich enzyme-linked immunoadsorbent assay.


RESULTS
VEGF and sCD44v6 levels in malignant ascites were 640.74+/-264.81 pg/ml and 89.22+/-38.20 ng/ml, respectively, both of which were significantly higher than those in cirrhotic ascites and tuberculous ascites (q=18.98, 11.89 and q=8.92, 5.09; P<0.01). However, the levels of VEGF and sCD44v6 in cirrhotic and tuberculous ascites had no significant difference (q=0.48, 0.75; P>0.05). Furthermore, VEGF levels in malignant ascites in patients with ovarian cancer were higher than those with gastric and colon cancer (q=5.03, 6.79; P<0.01, respectively). But differences of VEGF levels between gastric and colon cancer were not significant (q=1.90, P>0.05). Whereas, sCD44v6 levels in malignant ascites from patients with ovarian, gastric and colon cancer had no significant difference (q=0.06, 0.91, 0.35; P>0.05, respectively). In comparison with cirrhotic and tuberculous ascites, when the upper limit of its VEGF mean levels 119.44 pg/ml (70.90+/-48.54) and sCD44v6 mean levels 63.59 ng/ml (44.42+/-19.17) was taken as the minimum cutoff limit, the sensitivity and specificity of VEGF and sCD44v6 of this assay to the diagnosis of malignant ascites were 91.3%, 90.9% and 73.9%, 88.7% respectively.


CONCLUSIONS
Elevated levels of VEGF and sCD44v6 may be useful in differential diagnosis of benign and malignant ascites.
Dong
Wei-Guo
WG
Department of Gastroenterology, Renmin Hospital, Wuhan University, Wuhan 430060, Hubei Province, China. dongwg@public.wh.hb.cn
Sun
Xiao-Min
XM
Yu
Bao-Ping
BP
Luo
He-Sheng
HS
Yu
Jie-Ping
JP
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000175:diagnosis* / Q000209:etiology* / Q000378:metabolism; D014408:Biomarkers, Tumor; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000556:secondary; D003110:Colonic Neoplasms / Q000150:complications / Q000556:secondary; D003937:Diagnosis, Differential; D005260:Female; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D008113:Liver Neoplasms / Q000150:complications / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications* / Q000556:secondary; D010190:Pancreatic Neoplasms / Q000150:complications / Q000556:secondary; D010534:Peritoneal Neoplasms / Q000150:complications / Q000556:secondary; D014395:Peritonitis, Tuberculous / Q000150:complications*; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000150:complications / Q000556:secondary; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D014408:Biomarkers, Tumor; C112697:CD44v6 antigen; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D042461:Vascular Endothelial Growth Factor A